Inder S Anand

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. doi Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT
    Inder S Anand
    VA Medical Center, Cardiology 111 C, One Veterans Drive, Minneapolis, MN 55417, USA
    Eur J Heart Fail 15:511-8. 2013
  2. doi Design and performance of a multisensor heart failure monitoring algorithm: results from the multisensor monitoring in congestive heart failure (MUSIC) study
    Inder S Anand
    Veterans Administration Medical Center, Minneapolis, Minnesota, USA
    J Card Fail 18:289-95. 2012
  3. doi Monitoring changes in fluid status with a wireless multisensor monitor: results from the Fluid Removal During Adherent Renal Monitoring (FARM) study
    Inder S Anand
    VA Medical Center, Minneapolis, MN 55417, USA
    Congest Heart Fail 18:32-6. 2012
  4. ncbi Is too much neurohormonal blockade harmful?
    Inder S Anand
    VA Medical Center, One Veterans Drive, 111 C, Minneapolis, MN 55417, USA
    Curr Cardiol Rep 6:169-75. 2004
  5. pmc Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure
    Inder S Anand
    Department of Cardiology, Veterans Administration Medical Center, Minneapolis, MN 55417, USA
    Vasc Health Risk Manag 6:449-55. 2010
  6. doi Pathophysiology of anemia in heart failure
    Inder S Anand
    Heart Failure Program, VA Medical Center, 1, Veterans Drive, Minneapolis, MN 55417, USA
    Heart Fail Clin 6:279-88. 2010
  7. doi Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial
    Inder S Anand
    VA Medical Center, Cardiology, Minneapolis, MN 55417, USA
    Circ Heart Fail 1:34-42. 2008
  8. doi Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure
    Inder S Anand
    VA Medical Center, Cardiology 111 C, Minneapolis, Minn 55417, USA
    Circulation 120:1577-84. 2009
  9. ncbi Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial
    Inder S Anand
    VA Medical Center, Minneapolis, Minnesota, USA
    J Am Coll Cardiol 49:32-9. 2007
  10. doi Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial
    Inder S Anand
    Division of Cardiology 111 C, Veterans Affairs Medical Center, 1 Veterans Drive, Minneapolis, MN 55417, USA
    Circulation 119:969-77. 2009

Collaborators

Detail Information

Publications56

  1. doi Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT
    Inder S Anand
    VA Medical Center, Cardiology 111 C, One Veterans Drive, Minneapolis, MN 55417, USA
    Eur J Heart Fail 15:511-8. 2013
    ..This study was conducted to determine whether galectin-3, a β-galactoside-binding lectin, plays a role in the pathogenesis of heart failure (HF)...
  2. doi Design and performance of a multisensor heart failure monitoring algorithm: results from the multisensor monitoring in congestive heart failure (MUSIC) study
    Inder S Anand
    Veterans Administration Medical Center, Minneapolis, Minnesota, USA
    J Card Fail 18:289-95. 2012
    ....
  3. doi Monitoring changes in fluid status with a wireless multisensor monitor: results from the Fluid Removal During Adherent Renal Monitoring (FARM) study
    Inder S Anand
    VA Medical Center, Minneapolis, MN 55417, USA
    Congest Heart Fail 18:32-6. 2012
    ..The fluid monitoring system accurately tracked fluid and weight loss in patients during hemodialysis, supporting its use as a tool for the management of patient fluid status in disease states...
  4. ncbi Is too much neurohormonal blockade harmful?
    Inder S Anand
    VA Medical Center, One Veterans Drive, 111 C, Minneapolis, MN 55417, USA
    Curr Cardiol Rep 6:169-75. 2004
    ..This article reviews some of these studies and analyzes the possible causes of these observations...
  5. pmc Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure
    Inder S Anand
    Department of Cardiology, Veterans Administration Medical Center, Minneapolis, MN 55417, USA
    Vasc Health Risk Manag 6:449-55. 2010
    ..The safety of once-daily (qd) dosing of valsartan in heart failure (HF) patients is not known...
  6. doi Pathophysiology of anemia in heart failure
    Inder S Anand
    Heart Failure Program, VA Medical Center, 1, Veterans Drive, Minneapolis, MN 55417, USA
    Heart Fail Clin 6:279-88. 2010
    ..However, the hemodynamic and neurohormonal alterations could potentially have deleterious long-term consequences and may contribute to anemia's role as an independent risk factor for adverse outcomes...
  7. doi Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial
    Inder S Anand
    VA Medical Center, Cardiology, Minneapolis, MN 55417, USA
    Circ Heart Fail 1:34-42. 2008
    ..The aim of the present study was to investigate the relationship between the SBP-lowering effects of valsartan and its cardiovascular protective effects in this population...
  8. doi Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure
    Inder S Anand
    VA Medical Center, Cardiology 111 C, Minneapolis, Minn 55417, USA
    Circulation 120:1577-84. 2009
    ..Renin-angiotensin blockade medications improve outcomes in HF but are underutilized in HF patients with renal dysfunction because of safety concerns and a lack of evidence of their effectiveness...
  9. ncbi Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial
    Inder S Anand
    VA Medical Center, Minneapolis, Minnesota, USA
    J Am Coll Cardiol 49:32-9. 2007
    ....
  10. doi Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial
    Inder S Anand
    Division of Cardiology 111 C, Veterans Affairs Medical Center, 1 Veterans Drive, Minneapolis, MN 55417, USA
    Circulation 119:969-77. 2009
    ..Because mortality also was significantly reduced (optimal pharmacological therapy versus CRT-D only), an assessment of the true reduction in hospitalization rates must consider the competing risk of death and varying follow-up times...
  11. doi Anemia and chronic heart failure implications and treatment options
    Inder S Anand
    Heart Failure Program, VA Medical Center, Mail Stop111C, One Veterans Drive, Minneapolis, Minnesota 55417, USA
    J Am Coll Cardiol 52:501-11. 2008
    ....
  12. doi Introduction: anemia in heart failure
    Inder Anand
    University of Minnesota Medical School, Minneapolis, MN 55417, USA
    Heart Fail Rev 13:377-8. 2008
  13. doi Heart failure and anemia: mechanisms and pathophysiology
    Inder S Anand
    Department of Medicine, University of Minnesota Medical School, VA Medical Center 111C, Minneapolis, MN 55417, USA
    Heart Fail Rev 13:379-86. 2008
    ..However, the hemodynamic and neurohormonal alterations could potentially have deleterious long-term consequences and could contribute to anemia's role as an independent risk factor for adverse outcomes...
  14. doi Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial
    Inder S Anand
    Cardiology 111 C, VA Medical Center, 1 Veterans Drive, Minneapolis, MN 55417, USA
    Circulation 122:1387-95. 2010
    ..Growth-differentiation factor-15 (GDF-15) is emerging as a prognostic biomarker in patients with coronary artery disease. Little is known about GDF-15 as a biomarker in patients with heart failure...
  15. ncbi C-reactive protein in heart failure: prognostic value and the effect of valsartan
    Inder S Anand
    VA Medical Center, Minneapolis, MN 55417, USA
    Circulation 112:1428-34. 2005
    ..We assessed the prognostic value of CRP in patients randomized in Val-HeFT (Valsartan Heart Failure Trial) and studied changes in CRP that were associated with valsartan...
  16. doi Traditional and novel approaches to management of heart failure: successes and failures
    Inder S Anand
    Division of Cardiology, University of Minnesota Medical School, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455, USA
    Cardiol Clin 26:59-72, vi. 2008
    ....
  17. ncbi Syndromes of subacute mountain sickness
    Inder S Anand
    Heart Failure Program, VA Medical Center, and University of Minnesota Medical School, Minneapolis, 55417, USA
    High Alt Med Biol 5:156-70. 2004
    ..Thus, it appears that both these syndromes are human counterparts of brisket disease in cattle...
  18. doi Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial
    Inder S Anand
    VA Medical Center and University of Minnesota, Minneapolis, MN 55417, USA
    Circ Heart Fail 4:569-77. 2011
    ..Moreover, it is unclear whether treatments have a differential effect on morbidity and mortality across the spectrum of NP levels...
  19. ncbi Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT
    Inder S Anand
    VA Medical Center, Minneapolis, MN 55417, USA
    Circulation 112:1121-7. 2005
    ..Anemia is known to be a prognostic marker for patients with heart failure. However, little is known about the prognostic value of changes in hemoglobin (Hgb) over time or about the causes of anemia...
  20. doi Design of the Multi-Sensor Monitoring in Congestive Heart Failure (MUSIC) study: prospective trial to assess the utility of continuous wireless physiologic monitoring in heart failure
    Inder S Anand
    Veterans Administration Medical Center and University of Minnesota, Minneapolis, Minnesota 55417, USA
    J Card Fail 17:11-6. 2011
    ..Remote monitoring of heart failure (HF) patients may help in the early detection of acute HF decompensation before the onset of symptoms. Appropriate early intervention in these patients may reduce HF-related hospitalizations and costs...
  21. ncbi Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)
    Inder S Anand
    VA Medical Center and University of Minnesota, Minneapolis, Minn 55417, USA
    Circulation 107:1278-83. 2003
    ..We examined whether changes in brain natriuretic peptide (BNP) and norepinephrine (NE) over time are associated with corresponding changes in mortality and morbidity in the Valsartan Heart Failure Trial...
  22. doi Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial
    Thomas S Rector
    Department of Veterans Affairs Health Care System and Department of Medicine, University of Minnesota, Minneapolis, MN 55417, USA
    Circ Heart Fail 5:217-25. 2012
    ....
  23. ncbi Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
    J Card Fail 13:331-9. 2007
    ..Whether the fixed-dose combination produces a further regression of LV remodeling when added to renin-angiotensin and sympathetic inhibitors has not been documented...
  24. doi Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial
    Peter Carson
    Veterans Affairs Medical Center, Washington, DC 20422 0001, USA
    J Card Fail 15:835-42. 2009
    ..Limited data exist on QOL scores in African-American heart failure patients or on the prognostic value of theses scores in any population. Finally, the effect of FDC I/H on QOL scores, particularly in A-HeFT, is not known...
  25. ncbi Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial
    Jay N Cohn
    Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, Minn 55455, USA
    Circulation 108:1306-9. 2003
    ..The Valsartan Heart Failure Trial (Val-HeFT) provided the first opportunity to examine the long-term effects of an angiotensin receptor blocker on plasma aldosterone levels in patients with NYHA class II through IV heart failure...
  26. doi Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial
    Michael R Zile
    RHJ Department of Veterans Affairs Medical Center and Medical University of South Carolina, Division of Cardiology, Department of Medicine, Charleston, SC 29425, USA
    Circulation 121:1393-405. 2010
    ....
  27. ncbi Validation of a risk score for dying within 1 year of an admission for heart failure
    Thomas S Rector
    Center for Chronic Disease Outcomes Research, Veterans Administration Medical Center, Minneapolis, Minnesota 55417, USA
    J Card Fail 12:276-80. 2006
    ..A relatively simple risk score has been developed to determine the risk of dying within 1-year of an admission for heart failure. We wanted to evaluate the risk score's predictive validity...
  28. doi Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure
    Thomas S Rector
    Minneapolis Veterans Affairs Medical Center and Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55417, USA
    J Am Geriatr Soc 56:1021-7. 2008
    ..To characterize prescribing of carvedilol and controlled-release (CR) metoprolol for veterans with heart failure who were predominantly elderly (aged > or = 65) and to compare the time to first hospitalization or death...
  29. ncbi Predicting survival in heart failure
    Viorel G Florea
    Heart Failure Program, VA Medical Center, One Veterans Drive, 111 C, Minneapolis, MN 55417, USA
    Curr Cardiol Rep 9:209-17. 2007
    ..In this review we briefly list established predictive markers and discuss whether survival can accurately be predicted in this condition...
  30. ncbi Relationships between clinical assessments and patients' perceptions of the effects of heart failure on their quality of life
    Thomas S Rector
    Center for Chronic Disease Outcomes Research, Department of Veterans Affairs Medical Center, 152 2E, One Veterans Drive, Minneapolis, MN 55417, USA
    J Card Fail 12:87-92. 2006
    ..Hypothetically, most of the effects of heart failure on quality of life might be attributed to symptoms produced by the pathology. Relationships between measures of these concepts need to be quantified to test this conceptual model...
  31. doi Incidence of appropriate shock in implantable cardioverter-defibrillator patients with improved ejection fraction
    Niyada Naksuk
    Division of Cardiology, Veterans Administration Medical Center, and Cardiac Arrhythmia and Syncope Center, Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55417, USA
    J Card Fail 19:426-30. 2013
    ..There is insufficient information on the management of implantable-cardioverter defibrillator (ICD) patients with improved EF at generator replacement...
  32. pmc Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial
    Sanjiv J Shah
    Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Circ Heart Fail 6:184-92. 2013
    ..We sought to describe the baseline clinical characteristics of subjects enrolled in TOPCAT relative to other contemporary observational studies and randomized clinical trials of HFpEF...
  33. ncbi Surrogate end points in heart failure
    Inder S Anand
    University of Minnesota Medical School and Veterans Affairs Medical Center, Minneapolis, Minnesota, USA
    J Am Coll Cardiol 39:1414-21. 2002
    ..Other uses of possible surrogates are discussed, and the limitations in finding true surrogates are mentioned. At this time we conclude there is no well established surrogate in HF...
  34. doi Biomarkers
    Viorel G Florea
    Department of Medicine, University of Minnesota Medical School, 420 Delaware Street Southeast, Minneapolis, MN 55455, USA
    Heart Fail Clin 8:207-24. 2012
    ....
  35. ncbi Critical stenosis of aortic and mitral valves after mediastinal irradiation
    A Selcuk Adabag
    Divisions of Cardiology, Cardiovascular Surgery and Pathology Veterans Affairs Medical Center, Minneapolis, Minnesota 55405, USA
    Catheter Cardiovasc Interv 63:247-50. 2004
    ..We present a patient with critical aortic and mitral valve stenosis after mediastinal irradiation and discuss the natural history, treatment, and prognosis of radiation-associated valvular heart disease...
  36. doi Cardiac resynchronization therapy in patients with minimal heart failure: a systematic review and meta-analysis
    Selcuk Adabag
    Division of Cardiology, Veterans Administration Medical Center, and University of Minnesota, Minneapolis, Minnesota, USA
    J Am Coll Cardiol 58:935-41. 2011
    ....
  37. ncbi Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial
    Bradley A Bart
    Minnesota Heart Failure Consortium, Minneapolis, Minnesota, USA
    J Am Coll Cardiol 46:2043-6. 2005
    ..The purpose of this research was to assess the safety and efficacy of ultrafiltration (UF) in patients admitted with decompensated congestive heart failure (CHF)...
  38. ncbi Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction
    Y Chandrashekhar
    Division of Cardiology, VA Medical Center and University of Minnesota, Minneapolis, Minnesota 55417, USA
    J Am Coll Cardiol 43:295-301. 2004
    ..This study was designed to evaluate whether in vivo caspase inhibition can prevent myocardial contractile protein degradation, improve myocardial function, and attenuate ventricular remodeling...
  39. doi Sudden cardiac death in heart failure patients with preserved ejection fraction
    Selcuk Adabag
    Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, USA
    J Card Fail 18:749-54. 2012
    ..We examined the incidence and predictors of SCD in HFpEF in a large population sample...
  40. ncbi The role of arginine vasopressin and its receptors in the normal and failing rat heart
    Y Chandrashekhar
    Division of Cardiology, VA Medical Center, University of Minnesota, 1, Veterans Drive, Minneapolis, MN 55425, USA
    J Mol Cell Cardiol 35:495-504. 2003
    ..To evaluate the role of arginine vasopressin (AVP) in the normal and post-myocardial infarction (post-MI) hearts, and to investigate whether chronic AVP receptor antagonism can attenuate post-infarct ventricular remodeling...
  41. ncbi Pathogenesis of anemia in cardiorenal disease
    Inder S Anand
    Veterans Administration Medical Center, University of Minnesota, Minneapolis, Minnesota, USA
    Rev Cardiovasc Med 6:S13-21. 2005
    ..Thus, anemia, CHF, and CKD may be independently related to one another, and this relationship may have important implications for their management...
  42. ncbi Noninvasive assessment of left ventricular remodeling: concepts, techniques, and implications for clinical trials
    Inder S Anand
    Division of Cardiology, University of Minnesota Medical School and Veterans Administration Medical Center, Minneapolis, MN 55417, USA
    J Card Fail 8:S452-64. 2002
    ..Thus, to study the process of remodeling in practice and in clinical trials, we have relied on assessments and measurements derived from cardiac imaging tests...
  43. pmc Research needed to support clinical use of biomarkers as prognostic indicators for patients with heart failure
    Thomas S Rector
    Center for Chronic Disease Outcomes Research, VA Medical Center, One Veterans Drive, Minneapolis, MN 55417, USA
    Cardiol Res Pract 2010:453851. 2010
    ..Specific clinical applications need to be identified for informative analyses of data that emphasize the most directly applicable measures of predictive performance...
  44. ncbi Anemia and its relationship to clinical outcome in heart failure
    Inder Anand
    VA Medical Center, Minneapolis, Minn, USA
    Circulation 110:149-54. 2004
    ..The goal of this study was to investigate the relationship between anemia, severity of CHF, and clinical outcomes...
  45. ncbi Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial
    Inder Anand
    Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN, USA
    Lancet 364:347-54. 2004
    ..We aimed to measure the effects of long-term endothelin-blockade on left-ventricular (LV) remodelling and clinical outcomes in patients with chronic heart failure...
  46. ncbi Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure
    Joann Lindenfeld
    Department of Medicine, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Denver, CO 80262, USA
    Circulation 115:204-12. 2007
    ..We sought to examine the outcomes of NYHA class IV patients enrolled in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial to assess the potential benefits of CRT and CRT-D...
  47. ncbi The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT)
    Serge Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Card Fail 12:375-80. 2006
    ..Here, we examined its prognostic value in a large population of patients with chronic heart failure...
  48. ncbi Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial
    Lidia Staszewsky
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    J Card Fail 13:797-804. 2007
    ..Because little information is available about the population of patients with both syndromes, we assessed the characteristics and the independent contribution of COPD to outcomes in patients with stable chronic heart failure...
  49. ncbi Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data
    Serge Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Clin Chem 52:1528-38. 2006
    ..This work aimed to provide a direct comparison of the prognostic value of BNP and NT-proBNP in patients with chronic and stable HF...
  50. ncbi Incremental prognostic value of changes in B-type natriuretic peptide in heart failure
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Am J Med 119:70.e23-30. 2006
    ..We hypothesized that B-type natriuretic peptide changes during treatment of heart failure may provide independent information on disease progression and outcome in patients enrolled in the Val-HeFT trial...
  51. doi Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia
    Jalal K Ghali
    Wayne State University, Detroit, Mich, USA
    Circulation 117:526-35. 2008
    ..The Study of Anemia in Heart Failure Trial (STAMINA-HeFT) is the largest multicenter, randomized, double-blind, placebo-controlled trial to date evaluating the effect of treating anemia in HF...
  52. ncbi Chronic heart failure with preserved left ventricular ejection fraction: diagnostic and prognostic value of left atrial size
    Andrea Rossi
    Dipartimento di Scienze Biomediche e Chirurgiche, Sezione di Cardiologia Universita degli Studi di Verona, Verona, Italy, and Department of Clinical Cardiology, Royal Brompton Hospital, National Heart and Lung Institute, London, UK
    Int J Cardiol 110:386-92. 2006
    ..Data on prognostic markers in such patients are limited. We analyzed the prevalence and prognostic value of left atrial (LA) size in this condition...
  53. ncbi Effect of left ventricular scar size, location, and transmurality on left ventricular remodeling with healed myocardial infarction
    Stein Orn
    University of Bergen, Stavanger University Hospital, Stavanger, Norway
    Am J Cardiol 99:1109-14. 2007
    ..In conclusion, in the studied cohort, there was a linear relation between scar size and ejection fraction and LV volumes. This relation was independent of scar location and transmurality...
  54. doi Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial)
    Serge Masson
    Department of Cardiovascular Reearch, Istituto Mario Negri, Milan, Italy
    J Am Coll Cardiol 52:997-1003. 2008
    ..This study sought to evaluate the association between changes over time of N-terminal pro-brain natriuretic peptide (NT-proBNP) expressed in different ways and outcome in patients with stable and chronic heart failure (HF)...
  55. ncbi Ventricular remodeling in heart failure: a credible surrogate endpoint
    Marvin A Konstam
    J Card Fail 9:350-3. 2003
  56. ncbi Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure
    Roberto Latini
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Circulation 116:1242-9. 2007
    ..We assessed the prognostic value of circulating cardiac troponin T in patients with stable chronic HF with a traditional (cTnT) and a new precommercial highly sensitive assay (hsTnT)...